NovoCure NVCR Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$71.14M-190% | -$24.5M+34.3% | -$37.27M+7.1% | -$40.14M-17.0% | -$34.32M+47.9% | ||
| $4.12M-2.2% | $4.22M+15.2% | $3.66M+6.4% | $3.44M+3.6% | $3.33M+7.1% | ||
| $63.01M+218% | $19.82M-32.4% | $29.32M+12.2% | $26.14M-11.5% | $29.55M-52.9% | ||
| $712K-63.2% | $1.94M+742% | $230K-45.8% | $424K-81.2% | $2.26M+503% | ||
| $2.78M+40.0% | $1.98M+324% | -$886K-241% | $629K-84.0% | $3.94M+215% | ||
| -$5.12M-161% | $8.44M-66.0% | $24.83M+1,078% | $2.11M+113% | -$16.42M-181% | ||
| -$219K-143% | $513K-35.0% | $789K-86.7% | $5.92M+361% | -$2.27M-219% | ||
| -$2.04M+53.2% | -$4.37M-75.4% | -$2.49M-76.3% | -$1.41M+45.2% | -$2.58M— | ||
| -$2.84M-7.3% | -$2.64M-8.8% | -$2.43M-364% | $920K+182% | -$1.12M+8.8% | ||
| -$2.62M+30.1% | -$3.75M+41.5% | -$6.4M+0.9% | -$6.46M+2.9% | -$6.65M+0.3% | ||
| -$13.52M+24.9% | -$18M-188% | $20.57M+229% | -$15.94M+55.3% | -$35.67M-933% | ||
| $5.15M+5.2% | $4.9M-13.4% | $5.66M+3.1% | $5.49M-48.3% | $10.61M+18.7% | ||
| $110M-80.4% | $560M+203% | $185M-56.0% | $420M+250% | $120M-29.4% | ||
| $97.1M-55.6% | $218.78M+103% | $107.91M-71.5% | $378.53M+227% | $115.86M-36.8% | ||
| $7.75M-97.7% | $336.33M+371% | $71.44M+98.5% | $35.99M+656% | -$6.47M+70.9% | ||
| $0— | $0-100% | $99.98M— | $0— | $0— | ||
| $0-100% | $560.95M— | $0— | $0— | $0— | ||
| $0-100% | $1.52M— | $0-100% | $2.14M— | $0-100% | ||
| -$166K+100.0% | -$559.49M-657% | $100.52M+4,111% | $2.39M-54.5% | $5.25M+95.4% | ||
| -$130K— | —— | -$22K-108% | $265K+16.7% | $227K+277% | ||
| -$6.07M+97.5% | -$241.25M-225% | $192.51M+748% | $22.7M+162% | -$36.66M-58.7% | ||
| $4.96M-5.4% | $5.24M+84.5% | $2.84M+6.3% | $2.67M+1.1% | $2.65M-4.9% | ||
| -$3.88M-146% | $8.43M+146% | $3.43M-75.2% | $13.84M+178% | $4.97M-22.4% | ||
| -$2.62M+30.1% | -$3.75M+41.5% | -$6.4M+0.9% | -$6.46M+2.9% | -$6.65M+0.3% | ||
| $712K-63.2% | $1.94M+742% | $230K-45.8% | $424K-81.2% | $2.26M+503% | ||
| -$477K— | —— | -$890K+35.1% | -$1.37M-2,898% | $49K-95.1% | ||
| -$828K-104% | $23.46M+756% | -$3.58M-134% | $10.45M+21.4% | $8.61M-50.5% | ||
| -$219K-143% | $513K-35.0% | $789K-86.7% | $5.92M+361% | -$2.27M-219% | ||
| -$2.84M-7.3% | -$2.64M-8.8% | -$2.43M-364% | $920K+182% | -$1.12M+8.8% | ||
| $97.1M-55.6% | $218.78M+103% | $107.91M-71.5% | $378.53M+227% | $115.86M-36.8% | ||
| $556K— | —— | —— | —— | $0— | ||
| $792K+53.5% | $516K+39.5% | $370K-8.4% | $404K+59.7% | $253K-82.2% | ||
| $998K-36.9% | $1.58M-41.0% | $2.68M+65.5% | $1.62M-93.1% | $23.49M+2,028% | ||
| -$3.88M-146% | $8.43M+146% | $3.43M-75.2% | $13.84M+178% | $4.97M-22.4% | ||
| -$18.67M+18.5% | -$22.9M-253% | $14.92M+170% | -$21.42M+53.7% | -$46.28M-273% | ||
| -$18.67M+18.5% | -$22.9M-253% | $14.92M+170% | -$21.42M+53.7% | -$46.28M-273% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does NovoCure generate?
- NovoCure (NVCR) generated -$26.9M in operating cash flow over the trailing twelve months.
- What is NovoCure's free cash flow?
- After $21.2M of capital expenditures, NovoCure's free cash flow was -$48.1M over the trailing twelve months, up 33.4% year over year.
- Where does NovoCure's cash flow data come from?
- Every line is extracted from NovoCure's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
